Seeking Alpha

Dutch Trader

View as an RSS Feed
View Dutch Trader's Comments BY TICKER:
Latest  |  Highest rated
  • Emerging Markets: The New Defensives? [View article]
    I agree with you completely that the Netherlands and Germany offer some great opportunities. Companies such as Royal Dutch Shell, Arcadis, CSM, DSM, ING Group, Nutreco and Vopak are way undervalued.
    Aug 17, 2011. 04:45 AM | 2 Likes Like |Link to Comment
  • Drug Maker Dividend Stocks With Strong Growth Prospects [View article]
    Thanks for your great insight and constructive discussion, I will take another look at Novartis.

    Quality companies are very cheap right now, so we all get a chance to buy them.
    Aug 11, 2011. 12:09 PM | 1 Like Like |Link to Comment
  • Drug Maker Dividend Stocks With Strong Growth Prospects [View article]
    Why I prefer Roche more than Novartis.

    While waiting for new drugs to come to the market - and good progress is being made here with 7 out of 7 clinical studies coming out with good results - Roche is becoming more efficient.

    This was long overdue and especially a lower head count is helping here.

    The margin is improving and is very impressive at more than 38% now. Cash flow is very strong (Chf 7 bln accumulated in H1 2011) and will allow for more acquisitions.

    The PE is now at less than 10X 2012 consensus estimates in Chf. and underlying (in LC) profitabilty is rising quickly plus a very strong pipeline and almost no patent cliff are to be faced, cash flows can therefore be much stronger than with Roche's peers in the years ahead.

    The burden of the strong Chf. is not so important - peers like Novartis report in USD and make their numbers look much better that way. So this could be the next step for Roche as well.

    Meanwhile, the dividend is secure as stated again by the CEO and gives investors a fantastic current yield of 5,4% for 2011 to look forward to.
    Aug 11, 2011. 07:55 AM | 1 Like Like |Link to Comment
  • Drug Maker Dividend Stocks With Strong Growth Prospects [View article]
    Guys new CEO Joe Jimenez is doing what he can do within the frame work shaped by his predecessor. In my opinion the Alcon acquisition was far too expensive and takes a long time to add to earnings, but at least sales of Lucentis are doing well and can partly compensate for the income loss of some 30% of Novartis portfolio due to patents expiring.

    The diversification strategy is working quite well, but will lead to a hodgepodge of businesses that are quite unrelated. This weighs on the valuation of the shares and makes progress for the share price difficult.

    The dividend is indicated to rise further now. Share buy backs are also possible again.

    But as a healthcare/pharma investment the shares just lack focus and cost cutting is too much the issue still.

    Under current circumstances Novartis could be bought for the long run and for the dividend yield but I remain more positive about the three buy recommendations mentioned in the article.

    A good, large acquisition in the pharma/ biotech side would help, but financials do not allow for this yet (Alcon too recent).
    Aug 11, 2011. 07:27 AM | Likes Like |Link to Comment
  • Zurich Financial: Well Run, Well Capitalized, And Focused on Underlying Profitability [View article]
    Zurich Financial presented solid 2Q11 results, beating expectations and showed a stronger operational performance than other insurers. Cash flows and capital ratios remain strong and management remains committed to its dividend policy, which leaves the stock trading at a sustainable 10% dividend yield, which is extremely attractive.

    All in all, despite the strong Swiss Franc, which has put the stock under pressure, the low interest rates which limit insurance profitability and the weakening economic climate, Zurich is undervalued.

    Zurich financial’s business operating profit rose 25% y-o-y to USD 1283mln, which was 21% better than expected. Net profit was 88% higher than last year at USD 1328mln, but this was influenced by the sale of Zurich’s stake in New China Life insurance. But even excluding this, results were at least 24% above expectations. The solid results were a result of revenue growth (volume growth & margin improvement) in the Latin American and Asian activities, as well as margin improvement in both Europe and the US. Zurich comments that the positive trend accelerated in the 2nd quarter, despite the weakening economy and dropping interest rates. Pricing and cost control lead to an improvement of the combined ratio to 95.3% from 96.9% last year. The balance sheet continues to be strong, with a Swiss solvency metric of above 220%. The book value dropped some 11% to CHF 180 thanks to currency shifts and bond market movements, but this was much less than feared as Zurich had tactically hedged a large part of its equity exposure and sold Italian bonds (before market concerns about Italy emerged).

    Solid results, Zurich’s focus on operational improvements is paying off given the pricing trends. The stock trades at a 10% dividend yield, 6x 2012 earnings and 0.7x book value, too cheap for a company that delivers a 17.4% return on equity in the last quarter.
    Aug 11, 2011. 07:21 AM | Likes Like |Link to Comment
  • Drug Maker Dividend Stocks With Strong Growth Prospects [View article]
    Okay fair, Q2 results beat analyst expectations and yes they took a stake in Alcon, but one swallow does not yet make a summer!

    Let us see what next quarters bring and if you are right I send you a good bottle of Zacapa rum.
    Aug 11, 2011. 04:38 AM | Likes Like |Link to Comment
  • Why NIVS IntelliMedia Is Undervalued [View article]
    Possible fraud, but nothing has been proven.
    Aug 10, 2011. 09:00 AM | Likes Like |Link to Comment
  • ING's Divesting Strategy Will Lead to a Higher Stock Price [View article]
    Very good results indeed, only Mr. Market doesn't see it yet!
    Aug 4, 2011. 08:24 AM | Likes Like |Link to Comment
  • Lihua International: Meltdown Alert [View article]
    I am not familiar with LIWA and their business so I can't judge of Absaroka's report is good or wrong.

    The only thing I found funny was that they claim stock promotion as a red flag. I think it is a red flag if you don't do stock promotion at all. A company has to be open to the public at large. Let investors know what you are more conferences you go, how more visible you get. Visibility reduces the chances of fraud.
    Aug 2, 2011. 05:53 PM | 1 Like Like |Link to Comment
  • The selloff in midcaps may be signal the "end of the run" for the broader post-crisis bull market. Now that the debt ceiling impasse appears to have ended, investors are turning their attention to the global economic weakness, and they don’t like what they see. After gaining 22.4% during in the past year, the sector is looking expensive, with a PE ratio of ~20.  [View news story]
    We are already in a bear market since 2000!
    Aug 1, 2011. 04:01 PM | Likes Like |Link to Comment
  • Apple: iPhone, iPad Sales the New Growth Engine [View article]
    King, is that not with all the articles you read about Apple?

    But thanks for the input. I will not write about Apple anymore because everyone seems to know Apple, at least they say!
    Jul 31, 2011. 05:08 AM | Likes Like |Link to Comment
  • Apple: iPhone, iPad Sales the New Growth Engine [View article]
    You are a world citizen, but here in the Netherlands a lot of folks only invest in companies that are listed on Euronext Amsterdam. Philips Electronics, Randstad, Unilever, Royal Dutch Shell, ING, Aegon, Reed Elsevier, TomTom, etc. so they forget that there are more interesting stocks worldwide.

    Augustom what's your view on content providers for the smartphone business?

    I found an interesting marketplace (crowdfunding website)for apps:


    Jul 30, 2011. 04:13 PM | Likes Like |Link to Comment
  • Apple: iPhone, iPad Sales the New Growth Engine [View article]
    Btw I hardly write about very popular stocks anyone follows.

    Most articles on Seeking don't bring something new, because we don't want to be accused of illegal "crimes". If news is public available you never bring something new to the table. News can be new for people who didn't read it before.
    Jul 30, 2011. 03:17 PM | Likes Like |Link to Comment
  • Apple: iPhone, iPad Sales the New Growth Engine [View article]
    Thanks for your comment!

    Augustum, the original title was called "Chinese youth more and more important for Apple", but the title was changed by Seeking. Not everyone knows that Apple is already freaking popular in China (Emerging Markets) and is going to be even more popular there.

    In Europe and in the Netherlands many investors are focused on their own stock markets and companies, so those investors don't know a lot about foreign companies (stocks). In this case an American company.
    Jul 30, 2011. 01:38 PM | Likes Like |Link to Comment
  • Apple: iPhone, iPad Sales the New Growth Engine [View article]
    Additional information that I forgot to implement in the article:
    Jul 30, 2011. 07:42 AM | Likes Like |Link to Comment